NEW YORK, December 30, 2025, 23:30 ET — Market closed
- Bristol-Myers Squibb shares closed up 0.18% at $54.21 on Tuesday.
- U.S. stocks ended slightly lower in thin, year-end trading.
- Investors are watching Bristol-Myers’ early-January dividend record date and its Feb. 5 earnings report.
Bristol-Myers Squibb Co. shares closed up 0.18% at $54.21 on Tuesday, after trading between $53.92 and $54.35. The stock has ranged from $42.52 to $63.33 over the past 52 weeks. Bristol Myers Squibb Investors
The modest gain came as Wall Street drifted lower in holiday-thinned trade. “The growth rates are going to converge between technology and everything else next year,” said Mark Hackett, chief market strategist at Nationwide, as investors repositioned after a tech-led run; the S&P 500 slipped 0.14% and the Nasdaq fell 0.23%. Reuters
Why it matters now: income and calendar effects are back in focus going into the final trading day of 2025. Bristol-Myers said its board declared a quarterly dividend of 63 cents a share, payable Feb. 2, 2026, to shareholders of record as of Jan. 2, 2026. news.bms.com
A “shareholder of record” is the holder listed on the company’s books as of that date. U.S. exchanges set an ex-dividend date — the first day new buyers are no longer entitled to the upcoming payout — based on settlement timing.
Investors also have a near-term fundamental checkpoint on the calendar. Bristol-Myers said it will report fourth-quarter 2025 results on Feb. 5, 2026, with a conference call scheduled for 8:00 a.m. ET. Bristol Myers Squibb Investors
Peers were mostly weaker in Tuesday’s session. AbbVie fell 0.48%, while Merck slipped 0.53% and Pfizer was nearly flat, according to MarketWatch market data. MarketWatch+1
The broader healthcare tape was also subdued. The Health Care Select Sector SPDR ETF (XLV) ended down about 0.08%, underscoring the defensive sector’s muted move. StockAnalysis
For Bristol-Myers, traders continue to weigh the appeal of steady cash returns against the need to refresh its product portfolio as older medicines face rising competition. The stock’s tight Tuesday range points to limited conviction into the turn of the year.
Before the next session, liquidity is likely to stay thin, which can exaggerate small moves in both directions. The final day of the year often sees portfolio adjustments that are more about positioning than new information.
On the chart, Tuesday’s $53.92 intraday low is an immediate reference point for near-term support. The $63.33 52-week high remains the next clear upside marker if buyers step back in after year-end.
The next test for longer-term holders comes quickly: how the stock trades around early-January dividend timing, and what management says about demand trends and 2026 expectations when it reports results on Feb. 5.
